These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30367826)

  • 1. Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay.
    Anliker M; Schmidt CQ; Harder MJ; Ganchev G; von Zabern I; Höchsmann B; Schrezenmeier H; Weinstock C
    Transfusion; 2018 Dec; 58(12):2992-3002. PubMed ID: 30367826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
    Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
    J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.
    Luzzatto L; Gianfaldoni G
    Int J Hematol; 2006 Aug; 84(2):104-12. PubMed ID: 16926130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
    Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
    Front Immunol; 2020; 11():1460. PubMed ID: 32793201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis.
    Gullipalli D; Zhang F; Sato S; Ueda Y; Kimura Y; Golla M; Miwa T; Wang J; Song WC
    J Immunol; 2018 Aug; 201(3):1021-1029. PubMed ID: 29898960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.
    Risitano AM; Notaro R; Marando L; Serio B; Ranaldi D; Seneca E; Ricci P; Alfinito F; Camera A; Gianfaldoni G; Amendola A; Boschetti C; Di Bona E; Fratellanza G; Barbano F; Rodeghiero F; Zanella A; Iori AP; Selleri C; Luzzatto L; Rotoli B
    Blood; 2009 Apr; 113(17):4094-100. PubMed ID: 19179465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cryptantigen Th on paroxysmal nocturnal hemoglobinuria erythrocytes in association with a hemolytic exacerbation.
    Nakakuma H; Hidaka M; Nagakura S; Nishimura Y; Iwamoto N; Horikawa K; Kawaguchi T; Kagimoto T; Takatsuki K
    J Clin Invest; 1995 Jul; 96(1):201-6. PubMed ID: 7542278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
    Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
    Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
    Peffault de Latour R; Fremeaux-Bacchi V; Porcher R; Xhaard A; Rosain J; Castaneda DC; Vieira-Martins P; Roncelin S; Rodriguez-Otero P; Plessier A; Sicre de Fontbrune F; Abbes S; Robin M; Socié G
    Blood; 2015 Jan; 125(5):775-83. PubMed ID: 25477495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
    Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
    Front Immunol; 2019; 10():1639. PubMed ID: 31379839
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria.
    Zhang L; Chen JY; Kerr C; Cobb BA; Maciejewski JP; Lin F
    Leukemia; 2021 Apr; 35(4):1176-1187. PubMed ID: 32814838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halting targeted and collateral damage to red blood cells by the complement system.
    Jalink M; de Boer ECW; Evers D; Havinga MQ; Vos JMI; Zeerleder S; de Haas M; Jongerius I
    Semin Immunopathol; 2021 Dec; 43(6):799-816. PubMed ID: 34191092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
    DeZern AE; Brodsky RA
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):479-94. PubMed ID: 26043387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the role of complement in bystander hemolysis? Old concept, new insights.
    Evangelidis P; Evangelidis N; Vlachaki E; Gavriilaki E
    Expert Rev Hematol; 2024; 17(4-5):107-116. PubMed ID: 38708453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
    Parker CJ; Wiedmer T; Sims PJ; Rosse WF
    J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.